APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation
顯示簡易詮釋資料 統計資料| 欄位 | 內容 | 語言 |
|---|---|---|
dc.citation.epage |
661 | en_US |
dc.citation.issue |
6 | en_US |
dc.citation.spage |
649 | en_US |
dc.citation.volume |
13 | en_US |
dc.citation.woscount |
0 | en_US |
dc.contributor.author |
Kanda, Tatsuo | en_US |
dc.contributor.author |
Lau, George K. K. | en_US |
dc.contributor.author |
Wei, Lai | en_US |
dc.contributor.author |
Moriyama, Mitsuhiko | en_US |
dc.contributor.author |
Yu, Ming-Lung | en_US |
dc.contributor.author |
Chuang, Wang-Long | en_US |
dc.contributor.author |
Ibrahim, Alaaeldin | en_US |
dc.contributor.author |
Lesmana, Cosmas Rinaldi Adithya | en_US |
dc.contributor.author |
Sollano, Jose | en_US |
dc.contributor.author |
Kumar, Manoj | en_US |
dc.contributor.author |
Jindal, Ankur | en_US |
dc.contributor.author |
Sharma, Barjesh Chander | en_US |
dc.contributor.author |
Hamid, Saeed S. | en_US |
dc.contributor.author |
Dokmeci, A. Kadir | en_US |
dc.contributor.author |
Mamun-Al-Mahtab | en_US |
dc.contributor.author |
McCaughan, Geoffrey W. | en_US |
dc.contributor.author |
Wasim, Jafri | en_US |
dc.contributor.author |
Crawford, Darrell H. G. | en_US |
dc.contributor.author |
Kao, Jia-Horng | en_US |
dc.contributor.author |
Ooka, Yoshihiko | en_US |
dc.contributor.author |
Yokosuka, Osamu | en_US |
dc.contributor.author |
Sarin, Shiv Kumar | en_US |
dc.contributor.author |
Omata, Masao | en_US |
dc.contributor.department |
生物科技學院 | zh_TW |
dc.contributor.department |
College of Biological Science and Technology | en_US |
dc.date.accessioned |
2020-01-02T00:04:22Z | |
dc.date.available |
2020-01-02T00:04:22Z | |
dc.date.issued |
2019-11-01 | en_US |
dc.description.abstract |
In the direct-acting antiviral (DAA) era for hepatitis C virus (HCV) infection, sustained virological response (SVR) is very high, but close attention must be paid to the possible occurrence of hepatocellular carcinoma (HCC) and reactivation of hepatitis B virus (HBV) in patients with co-infection who achieved SVR in short term. HCC occurrence was more often observed in patients with previous HCC history. We found occurrence of HCC in 178 (29.6%) of 602 patients with previous HCC history (15.4 months mean follow-up post-DAA initiation) but, in contrast, in only 604 (1.3%) of 45,870 patients without previous HCC history (18.2 months mean follow-up). Thus, in these guidelines, we recommend the following: in patients with previous HCC history, surveillance at 4-month intervals for HCC by ultrasonography (US) and tumor markers should be performed. In patients without previous HCC history, surveillance at 6- to 12-month intervals for HCC including US is recommended until the long-term DAA treatment effects, especially for the resolution of liver fibrosis, are confirmed. This guideline also includes recommendations on how to follow-up patients who have been infected with both HCV and HBV. When HCV was eradicated in these HBsAg-positive patients or patients with previous HBV infection ( anti-HBc and/ or anti-HBs-positive), it was shown that HBV reactivation or HBV DNA reappearance was observed in 67 (41.4%) of 162 or 12 (0.9%) of 1317, respectively. For these co-infected patients, careful attention should be paid to HBV reactivation for 24 weeks post-treatment. | en_US |
dc.identifier.doi |
10.1007/s12072-019-09988-7 | en_US |
dc.identifier.issn |
1936-0533 | en_US |
dc.identifier.journal |
HEPATOLOGY INTERNATIONAL | en_US |
dc.identifier.uri |
http://dx.doi.org/10.1007/s12072-019-09988-7 | en_US |
dc.identifier.uri |
https://ir.lib.nycu.edu.tw/handle/11536/153411 | |
dc.identifier.wosnumber |
WOS:000498640900001 | en_US |
dc.language.iso |
en_US | en_US |
dc.subject |
HCV | en_US |
dc.subject |
HCC | en_US |
dc.subject |
DAA | en_US |
dc.subject |
SVR | en_US |
dc.subject |
Follow-up | en_US |
dc.subject |
Guideline | en_US |
dc.subject |
HBV | en_US |
dc.title |
APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation | en_US |
dc.type |
Article | en_US |
檔案
本條目沒有附加檔案。
所屬典藏: 期刊論文
引用此條目
Kanda, T., Lau, G. K. K., Wei, L., Moriyama, M., Yu, M.-L., Chuang, W.-L., Ibrahim, A., Lesmana, C. R. A., Sollano, J., Kumar, M., Jindal, A., Sharma, B. C., Hamid, S. S., Dokmeci, A. K., Mamun-Al-Mahtab, McCaughan, G. W., Wasim, J., Crawford, D. H. G., Kao, J.-H., … Omata, M. (2019). APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. HEPATOLOGY INTERNATIONAL, 13(6), 649–661. https://doi.org/10.1007/s12072-019-09988-7
引用文字依 APA 第 7 版格式自動產生,使用前請再核對。
分享
永久網址:https://ir.lib.nycu.edu.tw/handle/11536/153411